Showing 581 - 600 results of 699 for search '"William Harvey"', query time: 1.26s Refine Results
  1. 581
  2. 582
  3. 583
  4. 584
  5. 585
  6. 586
  7. 587
  8. 588
  9. 589
  10. 590
  11. 591
  12. 592
  13. 593
  14. 594

    Improved lung function and patient-reported outcomes with co-suspension delivery technology glycopyrrolate/formoterol fumarate metered dose inhaler in COPD: a randomized Phase III... by Lipworth BJ, Collier DJ, Gon Y, Zhong NS, Nishi K, Chen R, Arora S, Maes A, Siddiqui S, Reisner C, Martin UJ

    Published 2018-09-01
    “…Brian J Lipworth,1 David J Collier,2 Yasuhiro Gon,3 Nanshan Zhong,4 Koichi Nishi,5 Rongchang Chen,4 Samir Arora,6 Andrea Maes,7 Shahid Siddiqui,8 Colin Reisner,7,8 Ubaldo J Martin8 1Scottish Centre for Respiratory Research, Ninewells Hospital, University of Dundee, Dundee, Scotland, UK; 2William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK; 3Itabashi Hospital, Nihon University School of Medicine, Itabashi, Tokyo, Japan; 4Guangzhou Institute of Respiratory Health, State Key Laboratory of Respiratory Diseases, National Clinical Research Center of Respiratory Diseases, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, People’s Republic of China; 5Ishikawa Prefectural Central Hospital, Kanazawa, Ishikawa, Japan; 6Aventiv Research Inc., Columbus, OH, USA; 7Pearl – a member of the AstraZeneca group, Morristown, NJ, USA; 8AstraZeneca, Gaithersburg, MD, USA Background: COPD is a major global cause of mortality and morbidity. …”
    Get full text
    Article
  15. 595
  16. 596
  17. 597
  18. 598
  19. 599
  20. 600